Drug Type Bispecific antibody |
Synonyms TST006 |
Target |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | CN | 20 Sep 2024 | |
Neoplasms | Preclinical | - | - |